Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial.
Diabetes
Heart failure
Remote patient management
Telehealth
Telemedicine
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
received:
06
02
2024
accepted:
24
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
12
6
2024
Statut:
epublish
Résumé
The TIM-HF2 study demonstrated that remote patient management (RPM) in a well-defined heart failure (HF) population reduced the percentage of days lost due to unplanned cardiovascular hospital admissions or all-cause death during 1-year follow-up (hazard ratio 0.80) and all-cause mortality alone (HR 0.70). Higher rates of hospital admissions and mortality have been reported in HF patients with diabetes compared with HF patients without diabetes. Therefore, in a post-hoc analysis of the TIM-HF2 study, we investigated the efficacy of RPM in HF patients with diabetes. TIM-HF2 study was a randomized, controlled, unmasked (concealed randomization), multicentre trial, performed in Germany between August 2013 and May 2018. HF-Patients in NYHA class II/III who had a HF-related hospital admission within the previous 12 months, irrespective of left ventricular ejection fraction, and were randomized to usual care with or without added RPM and followed for 1 year. The primary endpoint was days lost due to unplanned cardiovascular hospitalization or due to death of any cause. This post-hoc analysis included 707 HF patients with diabetes. In HF patients with diabetes, RPM reduced the percentage of days lost due to cardiovascular hospitalization or death compared with usual care (HR 0.66, 95% CI 0.48-0.90), and the rate of all-cause mortality alone (HR 0.52, 95% CI 0.32-0.85). RPM was also associated with an improvement in quality of life (mean difference in change in global score of Minnesota Living with Heart Failure Questionnaire score (MLHFQ): - 3.4, 95% CI - 6.2 to - 0.6). These results support the use of RPM in HF patients with diabetes. ClinicalTrials.gov NCT01878630.
Sections du résumé
BACKGROUND
BACKGROUND
The TIM-HF2 study demonstrated that remote patient management (RPM) in a well-defined heart failure (HF) population reduced the percentage of days lost due to unplanned cardiovascular hospital admissions or all-cause death during 1-year follow-up (hazard ratio 0.80) and all-cause mortality alone (HR 0.70). Higher rates of hospital admissions and mortality have been reported in HF patients with diabetes compared with HF patients without diabetes. Therefore, in a post-hoc analysis of the TIM-HF2 study, we investigated the efficacy of RPM in HF patients with diabetes.
METHODS
METHODS
TIM-HF2 study was a randomized, controlled, unmasked (concealed randomization), multicentre trial, performed in Germany between August 2013 and May 2018. HF-Patients in NYHA class II/III who had a HF-related hospital admission within the previous 12 months, irrespective of left ventricular ejection fraction, and were randomized to usual care with or without added RPM and followed for 1 year. The primary endpoint was days lost due to unplanned cardiovascular hospitalization or due to death of any cause. This post-hoc analysis included 707 HF patients with diabetes.
RESULTS
RESULTS
In HF patients with diabetes, RPM reduced the percentage of days lost due to cardiovascular hospitalization or death compared with usual care (HR 0.66, 95% CI 0.48-0.90), and the rate of all-cause mortality alone (HR 0.52, 95% CI 0.32-0.85). RPM was also associated with an improvement in quality of life (mean difference in change in global score of Minnesota Living with Heart Failure Questionnaire score (MLHFQ): - 3.4, 95% CI - 6.2 to - 0.6).
CONCLUSION
CONCLUSIONS
These results support the use of RPM in HF patients with diabetes.
CLINICAL TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT01878630.
Identifiants
pubmed: 38867198
doi: 10.1186/s12933-024-02285-0
pii: 10.1186/s12933-024-02285-0
doi:
Banques de données
ClinicalTrials.gov
['NCT01878630']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Informations de copyright
© 2024. The Author(s).
Références
Scholte NTB, Gurgoze MT, Aydin D, Theuns D, Manintveld OC, Ronner E, Boersma E, de Boer RA, van der Boon RMA, Brugts JJ. Telemonitoring for heart failure: a meta-analysis. Eur Heart J. 2023;44:2911–26.
doi: 10.1093/eurheartj/ehad280
pubmed: 37216272
pmcid: 10424885
Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H, Stork S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F, Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018;392:1047–57.
doi: 10.1016/S0140-6736(18)31880-4
pubmed: 30153985
Pandey A, Khan MS, Patel KV, Bhatt DL, Verma S. Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes Endocrinol. 2023.
MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, Investigators C. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–85.
doi: 10.1093/eurheartj/ehn153
pubmed: 18413309
Lehrke M, Marx N. Diabetes Mellitus and Heart failure. Am J Med. 2017;130:S40–50.
doi: 10.1016/j.amjmed.2017.04.010
pubmed: 28526183
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. On behalf of the American Diabetes A. 1. Improving Care and promoting health in populations: standards of Care in Diabetes-2023. Diabetes Care. 2023;46:S10–8.
doi: 10.2337/dc23-S001
pubmed: 36507639
Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Winkler S, Vettorazzi E, Polze A, Stangl K, Hartmann O, Marx A, Neuhaus P, Scherf M, Kirwan BA, Anker SD. Telemedical Interventional Management in Heart failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention. Eur J Heart Fail. 2018;20:1485–93.
doi: 10.1002/ejhf.1300
pubmed: 30230666
Bradley J, Schelbert EB, Bonnett LJ, Lewis GA, Lagan J, Orsborne C, Brown PF, Naish JH, Williams SG, McDonagh T, Schmitt M, Miller CA. Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation study. Lancet Digit Health. 2022;4:e445–54.
doi: 10.1016/S2589-7500(22)00045-0
pubmed: 35562273
pmcid: 9130210
Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev. 2015;2015:CD007228.
pubmed: 26517969
pmcid: 8482064
Zhu Y, Gu X, Xu C. Effectiveness of telemedicine systems for adults with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2020;25:231–43.
doi: 10.1007/s10741-019-09801-5
pubmed: 31197564
Scholte NTB, Gurgoze MT, Aydin D, Theuns D, Manintveld OC, Ronner E, Boersma E, de Boer RA, van der Boon RMA, Brugts JJ. Telemonitoring for heart failure: a meta-analysis. Eur Heart J. 2023.
Yanicelli LM, Goy CB, Martínez EC, Herrera MC. Heart failure non-invasive home telemonitoring systems: a systematic review. Comput Methods Programs Biomed. 2021;201:105950.
doi: 10.1016/j.cmpb.2021.105950
pubmed: 33540328
Alvarez P, Sianis A, Brown J, Ali A, Briasoulis A. Chronic disease management in heart failure: focus on telemedicine and remote monitoring. Rev Cardiovasc Med. 2021;22:403–13.
doi: 10.31083/j.rcm2202046
pubmed: 34258907
Brahmbhatt DH, Cowie MR. Remote management of Heart failure: an overview of Telemonitoring technologies. Card Fail Rev. 2019;5:86–92.
doi: 10.15420/cfr.2019.5.3
pubmed: 31179018
pmcid: 6545972
Galinier M, Roubille F, Berdague P, Brierre G, Cantie P, Dary P, Ferradou JM, Fondard O, Labarre JP, Mansourati J, Picard F, Ricci JE, Salvat M, Tartiere L, Ruidavets JB, Bongard V, Delval C, Lancman G, Pasche H, Ramirez-Gil JF, Pathak A, Investigators O. Telemonitoring versus standard care in heart failure: a randomised multicentre trial. Eur J Heart Fail. 2020;22:985–94.
doi: 10.1002/ejhf.1906
pubmed: 32438483
Ong MK, Romano PS, Edgington S, Aronow HU, Auerbach AD, Black JT, De Marco T, Escarce JJ, Evangelista LS, Hanna B, Ganiats TG, Greenberg BH, Greenfield S, Kaplan SH, Kimchi A, Liu H, Lombardo D, Mangione CM, Sadeghi B, Sadeghi B, Sarrafzadeh M, Tong K, Fonarow GC. Better Effectiveness after Transition-Heart Failure Research G. Effectiveness of Remote Patient Monitoring after discharge of hospitalized patients with heart failure: the Better Effectiveness after transition -- heart failure (BEAT-HF) randomized clinical trial. JAMA Intern Med. 2016;176:310–8.
doi: 10.1001/jamainternmed.2015.7712
pubmed: 26857383
pmcid: 4827701
Felker GM, Sharma A, Mentz RJ, She L, Green CL, Granger BB, Heitner JF, Cooper L, Teuteberg J, Grodin JL, Rosenfield K, Hudson L, Kwee LC, Ilkayeva O, Shah SH. A Randomized Controlled Trial of Mobile Health Intervention in patients with heart failure and diabetes. J Card Fail. 2022;28:1575–83.
doi: 10.1016/j.cardfail.2022.07.048
pubmed: 35882260
Silva-Almodovar A, Nahata MC. Telehealth intervention to improve uptake of evidence-based medications among patients with type 2 diabetes and heart failure or Cardiovascular Disease. Int J Environ Res Public Health. 2023;20.
Glowczynska R, Piotrowicz E, Szalewska D, Piotrowicz R, Kowalik I, Pencina MJ, Zareba W, Banach M, Orzechowski P, Pluta S, Irzmanski R, Kalarus Z, Opolski G. Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. Cardiovasc Diabetol. 2021;20:106.
doi: 10.1186/s12933-021-01292-9
pubmed: 33985509
pmcid: 8120915
Drug Commission of German Pharmacists (AMK) DCotGMAA, Federal Association for Self-Help (BAG Selbsthilfe), German Diabetes Society (DDG), German Society for General Medicine and Family Medicine (DEGAM), German Society for Geriatrics (DGG), German Society For Internal Medicine (DGIM), German Society for Internal Intensive Care Medicine and Emergency Medicine (DGIIN), German Society for Cardiology-Heart and Circulation Research (DGK), German Society for Nephrology (DGFN), German Society for Palliative Medicine (DGP), German Society for Nursing Science (DGP), German Society for Pneumology and Respiratory Medicine (DGP), German Society for the Prevention and Rehabilitation of Cardiovascular Diseases (DGPR), German Society for Psychosomatic Medicine and Medical Psychotherapy (DGPM), German Society for Rehabilitation Sciences (DGRW), German Society for Sleep Research and Sleep Medicine (DGSM), German Society for Thoracic, Cardiac and Vascular Surgery (DGTHG), German College for Psychosomatic Medicine (DKPM), Medical Center for Quality in Medicine (ÄZQ). NVL Chronic Heart Failure– Long Version. 2019;3.